中国麻风皮肤病杂志 ›› 2019, Vol. 35 ›› Issue (8): 505-508.doi: 10.12144/zgmfskin201908505

• 综述 • 上一篇    下一篇

肥大细胞增生症病因与治疗研究进展

岳万波  徐倩玥  余红   

  1. 上海交通大学医学院附属新华医院皮肤科,200092
  • 出版日期:2019-08-15 发布日期:2019-08-19
  • 通讯作者: 余红，E-mail: smallgrass6@163.com

Mastocytosis: pathogenesis and treatment

YUE Wanbo, XU Qianyue, YU Hong   

  1. Xinhua Hospital Affiliated to Shanghai Jiaotong University, School of Medicine, Shanghai 200092, China
  • Online:2019-08-15 Published:2019-08-19
  • Contact: YU Hong, E-mail: smallgrass6@163.com

PDF (PC)

132

摘要： 2016年WHO更新了肥大细胞增生症（mastocytosis, MC）的分型和诊断标准，一些方法已经得到验证并应用于临床，包括：酪氨酸激酶抑制剂，单克隆抗体靶向治疗，细胞减灭术，造血干细胞移植等。本文对该病的分型、发病机制、目前常用和新兴治疗方法进行综述。

关键词: 肥大细胞增生症, 酪氨酸激酶抑制剂, 靶向治疗, 造血干细胞移植

Abstract: The classification and diagnosis of mastocytosis (MC) were renovated by WHO in 2016. Some new therapies have been used in treating MC, such as tyrosine kinase inhibitor, monoclonal antibody targeted therapy, cell reduction, hematopoietic stem cell transplantation, etc. The classification, pathogenesis, the common and new therapies are reviewed in this article.

Key words: mastocytosis, tyrosine kinase inhibitor, targeted therapy, hematopoietic stem cell transplantation